Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 3/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 2/20 | 0.38 |
| ▸ | MMP7 | P09237 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | MMP8 | P22894 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17102246 | 1.00 | CHRM2 (0.38) | CHRM2CHRM1MMP2MMP1MMP3 | |
| SCHEMBL18603267 | 1.00 | CHRM2 (0.38) | CHRM2CHRM1MMP2MMP1MMP3 | |
| SCHEMBL20981967 | 1.00 | CHRM2 (0.38) | CHRM2CHRM1MMP2MMP1MMP3 | |
| SCHEMBL16426901 | 0.85 | SMN1; SMN2 (0.40) | CHRM2CHRM1MMP2MMP1MMP3 | |
| SCHEMBL16426900 | 0.85 | SMN1; SMN2 (0.40) | CHRM2CHRM1MMP2MMP1MMP3 | |
| SCHEMBL19499084 | 0.85 | SMN1; SMN2 (0.40) | CHRM2CHRM1MMP2MMP1MMP3 | |
| SCHEMBL17121095 | 0.78 | SMN1; SMN2 (0.45) | CHRM2CHRM1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL18372655 | 0.77 | BRD4 (0.41) | MMP2GAALMNA | |
| SCHEMBL19947558 | 0.76 | SMN1; SMN2 (0.46) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL19965134 | 0.76 | SMN1; SMN2 (0.46) | MMP2MMP1MMP3MMP7MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INT (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INT (DE) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | HRH4, HRH2, HRH3 | CHRM2 58/4885CHRM1 68/4885MMP2 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.